The aim of this study is to assess if hypogonadic men with periodontitis benefit from testosterone replacement therapy before being submitted to periodontal treatment. Fifty hypogonadic men (Total Testosterone \<200ng/dL) will be recruited from the Clinics Hospital at Federal University of Paraná and subjected to periodontal evaluation by a trained and calibrated researcher. The subjects presenting with periodontitis (assessed by clinical parameters) will be randomly allocated to "testosterone replacement therapy" (TRT) group or "placebo" for 3 months. After that time, all patients will receive nonsurgical periodontal treatment, which will be reassessed after 45 days. Clinical parameters (such as probing depth, gingival and plaque index, clinical attachment loss, bleeding on probing), sub gingival plaque and gingival crevicular fluid will be collected at baseline, just before therapy and 45 days after therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Androgel (50mg testosterone), gel, daily
Placebo, gel, daily
Clínica de Odontologia da Universidade Federal do Paraná
Curitiba, Paraná, Brazil
CAL
Clinical Attachment Loss
Time frame: 4.5 months
PPD
probing pocket depth
Time frame: 4.5months
PPD
probing pocket depth
Time frame: 3months
BOP
bleeding on probing
Time frame: 3months
BOP
bleeding on probing
Time frame: 4.5months
Micro-organisms concentration
DNA hybridization - checkerboard
Time frame: 4.5months
Micro-organisms concentration
DNA hybridization - checkerboard
Time frame: 3months
Concentration of inflammatory markers in crevicular fluid
Multiplex assay
Time frame: 3months
Concentration of inflammatory markers in crevicular fluid
Multiplex assay
Time frame: 4.5 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.